Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMHM0RW)

Drug Name
6-(N-Phenylcarbamyl)-2-Naphthalenecarboxamidine Drug Info
Synonyms
6-(N-PHENYLCARBAMYL)-2-NAPHTHALENECARBOXAMIDINE; CHEMBL104937; 6-[(Z)-AMINO(IMINO)METHYL]-N-PHENYL-2-NAPHTHAMIDE; 6-carbamimidoyl-N-phenylnaphthalene-2-carboxamide; 1owe; uPa_7; AC1L9L6A; SCHEMBL4324160; ZINC2047486; BDBM50138670; 6-carbamimidoyl-N-phenyl-2-naphthamide; DB01977; 6-Carbamimidoyl-naphthalene-2-carboxylic acid phenylamide
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
447732
TTD Drug ID
DMHM0RW

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Targeting Urokinase-type plasminogen activator (PLAU)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pro-urokinase DMGKT2L Thrombin deficiency 3B14.Z Approved [2]
Urokinase DM0GOUD Myocardial infarction BA41-BA43 Approved [3]
PAI-1 DMY2AEF N. A. N. A. Phase 4 [4]
Amediplase DM4FPM3 Myocardial infarction BA41-BA43 Phase 3 [5]
Upamostat DMFZULI Breast cancer 2C60-2C65 Phase 2 [6]
Saruplase DM1M0PR Thrombosis DB61-GB90 Phase 2 [7]
HTU-PA DMNHE43 Cerebrovascular ischaemia 8B1Z Phase 1/2 [8]
PMID18163548C4 DMHPME3 Myocardial ischemia BA6Z Clinical trial [9]
UK-356202 DMSRK2A Myocardial hypertrophy BC45 Clinical trial [10]
PAI-2 DMRSMW8 N. A. N. A. Discontinued in Phase 2 [11]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Urokinase-type plasminogen activator (PLAU) TTGY7WI UROK_HUMAN Inhibitor [1]

References

1 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
2 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2393).
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Urokinase-type plasminogen activator and its inhibitor PAI-1: predictors of poor response to tamoxifen therapy in recurrent breast cancer. J Natl Cancer Inst. 1995 May 17;87(10):751-6.
5 Emerging drugs in peripheral arterial disease. Expert Opin Emerg Drugs. 2006 Mar;11(1):75-90.
6 Phase II randomised proof-of-concept study of the urokinase inhibitor upamostat (WX-671) in combination with gemcitabine compared with gemcitabine alone in patients with non-resectable, locally advanced pancreatic cancer. Br J Cancer. 2013 Mar 5;108(4):766-70.
7 Pharmacokinetics and pharmacodynamics of saruplase, an unglycosylated single-chain urokinase-type plasminogen activator, in patients with acute myocardial infarction. Thromb Haemost. 1994 Nov;72(5):740-4.
8 Characterization of the dexamethasone-induced inhibitor of plasminogen activator in HTC hepatoma cells. J Biol Chem. 1986 Mar 25;261(9):4352-7.
9 Fragment-based discovery of mexiletine derivatives as orally bioavailable inhibitors of urokinase-type plasminogen activator. J Med Chem. 2008 Jan 24;51(2):183-6.
10 Selective urokinase-type plasminogen activator (uPA) inhibitors. Part 3: 1-isoquinolinylguanidines. Bioorg Med Chem Lett. 2004 Jun 21;14(12):3227-30.
11 Topological localization of plasminogen activator inhibitor type 2. Cytometry. 2000 May 1;40(1):32-41.